Anti-cancer Drugs Associated Atrial Fibrillation-An Analysis of Real-World Pharmacovigilance Data.
FAERS
atrial fibrillation
cardiac adverse events
cardiotoxicity
chemotherapy
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
07
2021
accepted:
15
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Several anti-cancer drugs have been linked to new onset atrial fibrillation (AF) but the true association of these drugs with AF is unknown. The FDA Adverse Event Reporting System (FAERS), a publicly available pharmacovigilance mechanism provided by the FDA, collects adverse event reports from the United States and other countries, thus providing real-world data. To identify anti-cancer drugs associated with AF using the FAERS database. The FAERS database was searched for all drugs reporting AF as an adverse event (AE). The top 30 anti-cancer drugs reporting AF cases were shortlisted and analyzed. Proportional reporting ratio (PRR) was used to measure disproportionality in reporting of adverse events for these drugs. When analyzed for AF as a percentage of all reported AE for a particular drug, Ibrutinib had the highest percentage (5.3%) followed distantly by venetoclax (1.6%), bortezomib (1.6%), carfilzomib (1.5%), and nilotinib (1.4%). The percentage of cardiac AE attributable to AF was also highest for ibrutinib (41.5%), followed by venetoclax (28.4%), pomalidomide (23.9%), bortezomib (18.2%), and lenalidomide (18.2%). Drugs with the highest PRR for AF included ibrutinib (5.96, 95% CI= 5.70-6.23), bortezomib (1.65, 95% CI = 1.52-1.79), venetoclax (1.65, 95% CI = 1.46-1.85), carfilzomib (1.53, 95% CI = 1.33-1.77), and nilotinib (1.46, 95% CI = 1.31-1.63). While newer anti-cancer drugs have improved the prognosis in cancer patients, it is important to identify any arrhythmias they may cause early on to prevent increased morbidity and mortality. Prospective studies are needed to better understand the true incidence of new onset AF associated with anti-cancer drugs.
Sections du résumé
Background
UNASSIGNED
Several anti-cancer drugs have been linked to new onset atrial fibrillation (AF) but the true association of these drugs with AF is unknown. The FDA Adverse Event Reporting System (FAERS), a publicly available pharmacovigilance mechanism provided by the FDA, collects adverse event reports from the United States and other countries, thus providing real-world data.
Objectives
UNASSIGNED
To identify anti-cancer drugs associated with AF using the FAERS database.
Methods
UNASSIGNED
The FAERS database was searched for all drugs reporting AF as an adverse event (AE). The top 30 anti-cancer drugs reporting AF cases were shortlisted and analyzed. Proportional reporting ratio (PRR) was used to measure disproportionality in reporting of adverse events for these drugs.
Results
UNASSIGNED
When analyzed for AF as a percentage of all reported AE for a particular drug, Ibrutinib had the highest percentage (5.3%) followed distantly by venetoclax (1.6%), bortezomib (1.6%), carfilzomib (1.5%), and nilotinib (1.4%). The percentage of cardiac AE attributable to AF was also highest for ibrutinib (41.5%), followed by venetoclax (28.4%), pomalidomide (23.9%), bortezomib (18.2%), and lenalidomide (18.2%). Drugs with the highest PRR for AF included ibrutinib (5.96, 95% CI= 5.70-6.23), bortezomib (1.65, 95% CI = 1.52-1.79), venetoclax (1.65, 95% CI = 1.46-1.85), carfilzomib (1.53, 95% CI = 1.33-1.77), and nilotinib (1.46, 95% CI = 1.31-1.63).
Conclusions
UNASSIGNED
While newer anti-cancer drugs have improved the prognosis in cancer patients, it is important to identify any arrhythmias they may cause early on to prevent increased morbidity and mortality. Prospective studies are needed to better understand the true incidence of new onset AF associated with anti-cancer drugs.
Identifiants
pubmed: 35498039
doi: 10.3389/fcvm.2022.739044
pmc: PMC9051026
doi:
Types de publication
Journal Article
Langues
eng
Pagination
739044Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Ahmad, Thurlapati, Thotamgari, Grewal, Sheth, Gupta, Beedupalli and Dominic.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Blood Adv. 2017 Sep 08;1(20):1739-1748
pubmed: 29296820
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):1-9
pubmed: 33275682
JAMA Oncol. 2018 Mar 08;4(3):e174519
pubmed: 29285538
Front Pharmacol. 2018 Oct 16;9:1058
pubmed: 30386232
Am Heart J. 2012 Dec;164(6):918-24
pubmed: 23194493
Recent Results Cancer Res. 2018;212:69-85
pubmed: 30069625
Front Cardiovasc Med. 2021 Jan 22;8:610915
pubmed: 33553271
Haematologica. 2013 Nov;98(11):1753-61
pubmed: 23935022
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235443
Eur J Prev Cardiol. 2017 Sep;24(14):1555-1566
pubmed: 28617620
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3-10
pubmed: 11998548
Cancer Manag Res. 2019 Apr 02;11:2663-2675
pubmed: 31037034
N Engl J Med. 2019 May 30;380(22):2095-2103
pubmed: 31141631
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320
pubmed: 32353110
Rev Clin Exp Hematol. 2004 Jun 01;8(1):E4
pubmed: 16029970
Int J Cardiol. 2013 May 10;165(2):355-7
pubmed: 22989607
Haematologica. 2012 Jun;97(6):883-9
pubmed: 22271904
JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500
pubmed: 30573111
Haematologica. 2017 Oct;102(10):1796-1805
pubmed: 28751558
Europace. 2009 Dec;11(12):1579-86
pubmed: 19801562
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192-197
pubmed: 28838088
Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):483-6
pubmed: 11828828
Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):31-37.e13
pubmed: 27780690
JAMA. 2001 May 9;285(18):2370-5
pubmed: 11343485
Hematol Oncol. 2019 Oct;37(4):508-512
pubmed: 31335982
Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S120-3
pubmed: 15683477
J Clin Oncol. 2019 Aug 1;37(22):1946-1955
pubmed: 31188726
Acta Med Scand. 1973 May;193(5):425-9
pubmed: 4717323
Am J Hematol. 2019 Jul;94(7):780-785
pubmed: 31006890